A Multi-Center, Double-Masked, Randomized, One-Year Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle-Control in Subjects With Dry Eye Disease (DED)

Trial Profile

A Multi-Center, Double-Masked, Randomized, One-Year Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle-Control in Subjects With Dry Eye Disease (DED)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2015

At a glance

  • Drugs Isunakinra (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions
  • Sponsors Eleven Biotherapeutics
  • Most Recent Events

    • 28 May 2015 Status changed from recruiting to discontinued according to an Eleven Biotherapeutics media release.
    • 04 Mar 2015 According to Eleven Biotherapeutics media release, status changed from not yet recruiting to recruiting.
    • 26 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top